OCGO - Home

Pubblicazioni scientifiche

Le pubblicazioni mediche e scientifiche che descrivono i risultati della ricerca condotta nella Divisione di Oncologia Falck con il sostegno finanziario della Oncologia Ca’ Granda Onlus Fondazione sono consultabili mediante PubMed, National Library of Medicine, sui siti www.ncbi.nlm.nih.gov/sites/entrez , http://scholar.google.it . Per giudicare la rilevanza delle pubblicazioni in oncologia è utile verificare l' Impact Factor nel 2005 della rivista che presenta la ricerca consultando il sito http://library.aut.ac.ir/jcr.htm Le pubblicazioni dal 1999 ad oggi:

2011

First-line bevacizumab plus taxane-based chemotherapy for locally recurrent or metastatic breast cancer: safety and efficacy in an open-label study in 2,251 patients.
Smith IE, Pierga JY, Biganzoli L, Cortés-Funes H, Thomssen C, Pivot X, Fabi A, Xu B, Stroyakovskiy D, Franke FA, Kaufman B, Mainwaring P, Pienkowski T, De Valk B, Kwong A, González-Trujillo JL, Koza I, Petrakova K, Pereira D, Pritchard KI; ATHENA Study Group
Annals Oncology 2011 Mar;22(3):595-602.

No improvement of survival with reduced- versus high-intensity conditioning for allogeneic stem cell transplants in Ewing tumor patients.
Thiel U, Wawer A, Wolf P, Badoglio M, Santucci A, Klingebiel T, Basu O, Borkhardt A, Laws HJ, Kodera Y, Yoshimi A, Peters C, Ladenstein R, Pession A, Prete A, Urban EC, Schwinger W, Bordigoni P, Salmon A, Diaz MA, Afanasyev B, Lisukov I, Morozova E, Toren A, Bielorai B, Korsakas J, Fagioli F, Caselli D, Ehninger G, Gruhn B, Dirksen U, Abdel-Rahman F, Aglietta M, Mastrodicasa E, Torrent M, Corradini P, Demeocq F, Dini G, Dreger P, Eyrich M, Gozdzik J, Guilhot F, Holler E, Koscielniak E, Messina C, Nachbaur D, Sabbatini R, Oldani E, Ottinger H, Ozsahin H, Schots R, Siena S, Stein J, Sufliarska S, Unal A, Ussowicz M, Schneider P, Woessmann W, Jürgens H, Bregni M, Burdach S
Annals Oncology 2011 Jul;22(7):1614-1621.

2010

Molecularly targeted therapies for colorectal cancer: Strategies for implementing translational research in clinical trials.
Zwierzina H, Bardelli A, Ciardiello F, Gariboldi M, Håkansson L, Lambrechts D, Lind GE, Loeffler-Ragg J, Schmoll H, Siena S, Tabernero J, Van Cutsem E
Current Opinion in Molecular Therapeutics 12(6):703-711

Randomized, phase 3 study (PRIME) of panitumumab with FOLFOX4 versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer.
Douillard JY, Siena S, Cassidy J, Tabernero J, Burkes R, Barugel M, Humblet Y, Bodoky G, Cunningham D, Jassem J, Rivera F, Kocákova I, Ruff P, Błasińska-Morawiec M, Šmakal M,
Canon JL, Rother M, Oliner KS, Wolf M, Gansert J
Journal Clinical Oncology 28(31):4967-705

Therapeutic implications of resistance to molecular therapies in metastatic colorectal cancer.
Sartore-Bianchi A, Bencardino K, Cassingena A, Venturini F, Funaioli C, Cipani T, Amatu A, Pietrogiovanna L, Schiavo R, Di Nicolantonio F, Artale F, Bardelli A, Siena S
Cancer Treatment Reviews 36 Suppl 3:S1-5

Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab.
De Roock W, Jonker DJ, Di Nicolantonio F, Sartore-Bianchi A, Tu D, Siena S*, Lamba S, Arena S, Frattini M, Piessevaux H, Van Cutsem E, O'Callaghan CJ, Khambata-Ford S, Zalcberg JR, Simes J, Karapetis CS, Bardelli A, Tejpar S
JAMA 304(16):1812-1820

Reply to E. Hawkes and D. Cunningham.
Bardelli A, Siena S
Journal Clinical Oncology
[Epub ahead of print]

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.
De Roock W, Claes B, Bernasconi D, De Schutter J, Biesmans B, Fountzilas G, Kalogeras KT, Kotoula V, Papamichael D, Laurent-Puig P, Penault-Llorca F, Rougier P, Vincenzi B, Santini D, Tonini G, Cappuzzo F, Frattini M, Molinari F, Saletti P, De Dosso S, Martini M, Bardelli A, Siena S, Sartore-Bianchi A, Tabernero J, Macarulla T, Di Fiore F, Gangloff AO, Ciardiello F, Pfeiffer P, Qvortrup C, Hansen TP, Van Cutsem E, Piessevaux H, Lambrechts D, Delorenzi M, Tejpar S
Lancet Oncology 11(8):753-762

Integrated molecular dissection of the epidermal growth factor receptor (EGFR) oncogenic pathway to predict response to EGFR-targeted monoclonal antibodies in metastatic colorectal cancer.
Sartore-Bianchi A, Bencardino K, Di Nicolantonio F, Pozzi F, Funaioli C, Gambi V, Arena S, Martini M, Lamba S, Cassingena A, Schiavo R, Bardelli A, Siena S
Targeted Oncology
[Epub ahead of print]

Dose-dense temozolomide regimen for the treatment of brain metastases from melanoma, breast cancer, or lung cancer not amenable to surgery or radiosurgery: a multicenter phase II study.
Siena S, Crinò L, Danova M, Del Prete S, Cascinu S, Salvagni S, Schiavetto I, Vitali M, Bajetta E
Annals Oncology 21(3):655-61

Molecular mechanisms of resistance to cetuximab or panitumumab in colorectal cancer.
Bardelli A, Siena S
Journal Clinical Oncology 28(7):1254-61

Reduced incidence of infusion-related reactions in metastatic colorectal cancer during treatment with cetuximab plus irinotecan with combined corticosteroid and antihistamine premedication.
Siena S, Glynne-Jones R, Thaler J, Adenis A, Preusser P, Aguilar EA, Aapro MS, Loos AH, Esser R, Berghoff K, Wilke H
Cancer 116(7):1827-1837

Malignant peritoneal mesothelioma: a multicenter study on 81 cases.
de Pangher Manzini V, Recchia L, Cafferata M, Porta C, Siena S, Giannetta L, Morelli F, Oniga F, Bearz A, Torri V, Cinquini M
Annals Oncology 21(2):348-53

Molecular mechanisms of resistance to cetuximab or panitumumab in colorectal cancer.
Bardelli A, Siena S
Epub

2009

Phase II study of cetuximab in combination with cisplatin and docetaxel in patients with untreated advanced gastric or gastro-oesophageal junction adenocarcinoma (DOCETUX study).
Pinto C, Di Fabio F, Barone C, Siena S, Falcone A, Cascinu S, Rojas Llimpe FL, Stella G, Schinzari G, Artale S, Mutri V, Giaquinta S, Giannetta L, Bardelli A, Martoni AA
British Journal of Cancer 101(8):1261-8

Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer.
Siena S, Sartore-Bianchi A, Di Nicolantonio F, Balfour J, Bardelli A
Journal of the National Cancer Institute 101(19):1308-1324

Multi-determinants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancer.
Sartore-Bianchi A, Di Nicolantonio F, Nichelatti M, Molinari F, De Dosso S, Saletti P, Martini M, Cipani T, Marrapese G, Mazzucchelli L, Lamba S, Veronese S, Frattini M, Bardelli A, Siena S
PLoS One 2;4(10):e7287

Phase II multicenter, uncontrolled trial of sorafenib in patients with metastatic breast cancer.
Bianchi G, Loibl S, Zamagni C, Salvagni S, Raab G, Siena S, Laferriere N, Peña C, Lathia C, Bergamini L, Gianni L
Anticancer Drugs 20(7):616-624

Sunitinib treatment in pediatric patients with advanced GIST following failure of imatinib.
Janeway KA, Albritton KH, Van Den Abbeele AD, D'Amato GZ, Pedrazzoli P, Siena S, Picus J, Butrynski JE, Schlemmer M, Heinrich MC, Demetri GD
Pediatr Blood Cancer 52(7):767-771

Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an openlabel randomised phase III trial.
Pirker R, Pereira JR, Szczesna A, von Pawel J, Krzakowski M, Ramlau R, Vynnychenko I, Park K, Yu CT, Ganul V, Roh JK, Bajetta E, O'Byrne K, de Marinis F, Eberhardt W, Goddemeier T, Emig M, Gatzemeier U; Siena S member of the FLEX Study Team
Lancet Oncology 373(9674):1525-1531

An expanded access program of erlotinib (Tarceva) in patients with advanced non-small cell lung cancer (NSCLC): Data report from Italy.
Tiseo M, Gridelli C, Cascinu S, Crinò L, Piantedosi FV, Grossi F, Brandes AA, Labianca R, Siena S, Amoroso D, Belvedere O, Valentino B, Bearz A, Venturino P, Ardizzoni A
Lung Cancer

Malignant peritoneal mesotelioma - Results from the International Expanded Access Program using pemetrexed alone or in combination with a platinum agent.
Carteni G, Manegold C, Garcia GM, Siena S, Zielinski CC, Amadori D, Liu Y, Blatter J, Visseren - Grul C, Stahel R
Lung Cancer 2009 May;64(2):211-218

Association of progression-free survival, overall survival, and patient-reported outcomes by skin toxicity and KRAS status in patients receiving panitumumab monotherapy.
Peeters M, Siena S, Van Cutsem E, Sobrero A, Hendlisz A, Cascinu S, Kalofonos H, Devercelli G, Wolf M, Amado RG
Cancer 115(7):1544-1554

PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies.
Sartore-Bianchi A, Martini M, Molinari F, Veronese S, Nichelatti M, Artale S, Di Nicolantonio F, Saletti P, De Dosso S, Mazzucchelli L, Frattini M, Siena S, Bardelli A
Cancer Research 69(5):1851-1857

Iron supplementation and erythropoiesisstimulatory agents in the treatment of cancer anemia.
Pedrazzoli P, Rosti G, Secondino S, Siena S
Cancer 115:1169-1173

2008

Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.
Di Nicolantonio F, Martini M, Molinari F, Sartore-Bianchi A, Arena S, Saletti P, De Dosso S, Mazzucchelli L, Frattini M, Siena S, Bardelli A
Journal Clinical Oncology 26(35):5705-5712

Cetuximab plus irinotecan in heavily pretreated metastatic colorectal cancer progressing on irinotecan: MABEL Study
Wilke H, Glynne-Jones R, Thaler J, Adenis A, Preusser P, Aranda E, Aapro M, Esser R, Loos AH, Siena S
Journal Clinical Oncology 26(33):5335-43

Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer
Di Nicolantonio F, Martini M, Molinari F, Sartore-Bianchi A, Arena S, Saletti P, De Dosso S, Mazzucchelli L, Frattini M, Siena S, Bardelli A
Epub

A phase II randomized multicenter trial of gefitinib plus FOLFIRI and FOLFIRI alone in patients with metastatic colorectal cancer.
Santoro A, Comandone A, Rimassa L, Granetti C, Lorusso V, Oliva C, Ronzoni M, Siena S, Zuradelli M, Mari E, Pressiani T, Carnaghi C
Annals Oncology 19(11):1888-93

Iron supplementation during treatment with erythropoiesis-stimulating agents for cancer-related anemia.
Schiavetto I, Pedrazzoli P, Basilico V, Siena S
Chemotherapy 54(6):417-420

Antitumor effect of allogeneic hematopoietic stem cell transplantation in
Secondino S, Pedrazzoli P, Schiavetto I, Basilico V, Bramerio E, Massimino M, Gambacorta M, Siena S
Bone Marrow Transplant 42(2):131-3

Palliative treatment for elderly patients with colon cancer in ten Italian medical oncology units.
Pasetto LM, Falci C, Rizzo E, De Salvo GL, Gasparini G, D'Andrea M, Bajetta E, Platania M, Alabiso O, Miraglia S, Oniga F, Biason R, Chetrì MC, Fedele P, Massara G, Romaniello I,
Giordano M, Luchena G, Buzzi F, Ricotta R, Siena S, Monfardini S
Anticancer Research 28(3B):1813-1820

First-line single-agent cetuximab in patients with advanced colorectal cancer.
Pessino A, Artale S, Sciallero S, Guglielmi A, Fornarini G, Andreotti IC, Mammoliti S, Comandini D, Caprioni F, Bennicelli E, Andretta V, Siena S, Sobrero A
Annals Oncology 19(4):711-6

Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer
Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ, Juan T, Sikorski R, Suggs S, Radinsky R, Patterson SD, Chang DD
Journal Clinical Oncology 26(10):1626-34

Randomized trial of intravenous iron supplementation in patients with chemotherapy-related anemia without iron
Pedrazzoli P, Farris A, Del Prete S, Del Gaizo F, Ferrari D, Bianchessi C, Colucci G, Desogus A, Gamucci T, Pappalardo A, Fornarini G, Pozzi P, Fabi A, Labianca R, Di Costanzo F, Secondino S, Crucitta E, Apolloni F, Del Santo A, Siena S
Journal Clinical Oncology 26(10):1619-1625

Antitumor effect of allogeneic hematopoietic stem cell transplantation in
Secondino S, Pedrazzoli P, Schiavetto I, Basilico V, Bramerio E, Massimino M, Gambacorta M, Siena S
Epub

EGFR FISH in colorectal cancer: what is the current reality?
Moroni M, Sartore-Bianchi A, Veronese S, Siena S
Lancet Oncology 9(5):402-403

Controversial evaluation of EGFR protein and gene status in predicting response to anti-EGFR monoclonal antibodies in metastatic colorectal cancer: a case report and review of the literature.
Moroni M, Veronese S, Sartore-Bianchi A, Artale S, Siena S
Targeted Oncology 3:127-130

An open-label, single-arm study assessing safety and efficacy of panitumumab in patients with metastatic colorectal cancer refractory to standard chemotherapy.
Van Cutsem E, Siena S, Humblet Y, Canon JL, Maurel J, Bajetta E, Neyns B, Kotasek D, Santoro A, Scheithauer W, Spadafora S, Amado RG, Hogan N, Peeters M
Annals Oncology 19(1):92-98

Cetuximab plus gemcitabine and cisplatin compared with gemcitabine and cisplatin alone in patients with advanced pancreatic cancer: a randomised, multicentre, phase II trial.
Cascinu S, Berardi R, Labianca R, Siena S, Falcone A, Aitini E, Barni S, Di Costanzo F, Dapretto E, Tonini G, Pierantoni C, Artale S, Rota S, Floriani I, Scartozzi M, Zaniboni A; Italian Group for the Study of Digestive Tract Cancer (GISCAD)
Lancet Oncology 9(1):39-44

Mutations of KRAS and BRAF in primary and matched metastatic sites of colorectal cancer
Artale S, Sartore-Bianchi A, Veronese SM, Gambi V, Sarnataro CS, Gambacorta M, Lauricella C, Siena S
Journal Clinical Oncology 26:4217-4219

Neuroimaging abnormalities in adult medulloblastoma undergoing intensified therapy.
Secondino S, Citterio A, Pedrazzoli P, Funaiolo C, Scialfa GG, Siena S
Anticancer Research 28:3991-3992

2007

Association of progression-free survival with patient-reported outcomes and survival: results from a randomised phase 3 trial of panitumumab.
Siena S, Peeters M, Van Cutsem E, Humblet Y, Conte P, Bajetta E, Comandini D, Bodoky G, Van Hazel G, Salek T, Wolf M, Devercelli G, Woolley M, Amado RG
British Journal Cancer 97(11):1469-1474

Darbepoetin alpha coming of age.
Pedrazzoli P, Cinieri S, Lorusso V, Gamucci T, Secondino S, Silvestris N
Anticancer Research 27:4419-4424

High-dose chemotherapy with autologous hematopoietic stem cell support for solid tumors in adults.
Pedrazzoli P, Rosti G, Secondino S, Carminati O, Demirer T; European Group for Blood and Marrow Transplantation; Solid Tumors Working Party; Gruppo Italiano per il Trapianto di Midollo Osseo, Cellule Staminali Emopoietiche e Terapia Cellulare
Semin Hematology 44:286-295

Germ-cell tumors.
De Giorgi U, Pedrazzoli P, Rosti G; Italian Germ-Cell Cancer Group; Gruppo Italiano per il Trapianto di Midollo Osseo, Cellule Staminali Emopoietiche e Terapia Cellulare
New England Journal Medicine 357:1773

Are metastatic testicular tumors curable with high-dose chemotherapy and stem-cell rescue?
Rosti G, De Giorgi U, Pedrazzoli P
Nature Clinical Practice. Oncology

Establishment and characterization of a new Ewing's sarcoma cell line from a malignant pleural effusion.
Schiavo R, Tullio C, La Grotteria M, Andreotti IC, Scarpati B, Romiti L, Bozzi F, Pedrazzoli P, Siena S
Anticancer Research 27(5A):3273-3278

Colorectal cancer treatment in elderly patients: results of a retrospective analysis addressed to the chiefs of medical oncology units in Italy.
Pasetto LM, Falci C, Basso U, Gasparini G, D'Andrea M, Bonginelli P, Bajetta E, Platania M, Alabisio O, Miraglia S, Bertona E, Oniga F, Biason R, Chetrì MC, Fedele P, Massara G, Romaniello I, Negru ME, Giordano M, Luchena G, Buzzi F, Ricotta R, Siena S, Monfardini S
Anticancer Research 27(5B):3601, 3603-3608

GMP production of anti-tumor cytotoxic T-cell lines for adoptive T-cell therapy in patients with solid neoplasia.
Turin I, Pedrazzoli P, Tullio C, Montini E, La Grotteria MC, Schiavo R, Perotti C, Locatelli F, Carretto E, Maccario R, Siena S, Montagna D
Cytotherapy 9(5):499-507

Epidermal growth factor receptor gene copy number and clinical outcome of metastatic colorectal cancer treated with panitumumab.
Sartore-Bianchi A, Moroni M, Veronese S, Carnaghi C, Bajetta E, Luppi G, Sobrero A, Barone C, Cascinu S, Colucci G, Cortesi E, Nichelatti M, Gambacorta M, Siena S
Journal Clinical Oncology 25(22):3238-3245

Gemcitabine plus cisplatin versus gemcitabine plus carboplatin as first-line chemotherapy in advanced transitional cell carcinoma of the urothelium: results of a randomized phase 2 trial.
Dogliotti L, Carteni G, Siena S, Bertetto O, Martoni A, Bono A, Amadori D, Onat H, Marini L
European Urology 52(1):134-141

Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in copy number patients with chemotherapy-refractory metastatic colorectal cancer.
Van Cutsem E, Peeters M, Siena S, Humblet Y, Hendlisz A, Neyns B, Canon JL, Van Laethem JL, Maurel J, Richardson G, Wolf M, Amado RG
Journal Clinical Oncology 25(13):1658-1664

Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies.
Benvenuti S, Sartore-Bianchi A, Di Nicolantonio F, Zanon C, Moroni M, Veronese S, Siena S, Bardelli A
Cancer Research 67(6):2643-2648

Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study).
Pinto C, Di Fabio F, Siena S, Cascinu S, Rojas Llimpe F, Ceccarelli C, Mutri V, Giannetta L, Giaquinta S, Funaioli C, Berardi R, Longobardi C, Piana E, Martoni A
Annals Oncology 18(3):510-517

Rationale and clinical results of multi-target treatments in oncology.
Sartore-Bianchi A, Ricotta R, Cerea G, Maugeri MR, Siena S
International Journal Biological Markers 22 (1 Suppl 4):S77-87

Reduced intensity stem cell transplantation for advanced soft tissue sarcomas in adults: a retrospective analysis of the European Group for Blood and Marrow Transplantation.
Secondino S, Carrabba MG, Pedrazzoli P, Castagna L, Spina F, Grosso F, Bertuzzi A, Bay JO, Siena S, Corradini P, Niederwieser D, Demirer T; European Group for Blood and Marrow Transplantation Solid Tumors Working Party
Haematologica 92(3):418-420

Tumor-associated embryonic antigen-expressing vaccines that target CCR6 elicit potent CD8+ T cell-mediated protective and therapeutic antitumor immunity.
Biragyn A, Schiavo R, Olkhanud P, Sumitomo K, King A, McCain M, Indig FE, Almanzar G, Baatar D
Journal Immunology 179:1381-1388

2006

Long-term results of a risk-adapted approach to melphalan conditioning in autologous peripheral blood stem cell transplantation for primary (AL) amyloidosis.
Perfetti V, Siena S, Palladini G, Bregni M, Di Nicola M, Obici L, Magni M, Brunetti L, Gianni AM, Merlini G
Haematologica 91(12):1635-1643

Pegfilgrastim: current and future perspectives in the treatment of chemotherapy-induced neutropenia.
Ricotta R, Cerea G, Schiavetto I, Maugeri MR, Pedrazzoli P, Siena S
Future Oncology 2(6):667-676

High dose chemotherapy with autologous hematopoietic stem cell support for solid tumors other than breast cancer in adults.
Pedrazzoli P, Ledermann JA, Lotz JP, Leyvraz S, Aglietta M, Rosti G, Champion KM, Secondino S, Selle F, Ketterer N, Grignani G, Siena S, Demirer T; European Group for Blood and Marrow Transplantation (EBMT) Solid Tumors Working Party
Annals Oncology 17(10):1479-1488

Allogeneic haematopoietic stem cell transplantation for metastatic renal carcinoma in Europe.
Barkholt L, Bregni M, Remberger M, Blaise D, Peccatori J, Massenkeil G, Pedrazzoli P, Zambelli A, Bay JO, Francois S, Martino R, Bengala C, Brune M, Lenhoff S, Porcellini A, Falda M, Siena S, Demirer T, Niederwieser D, Ringden O; French ITAC group and the EBMT Solid Tumour Working Party
Annals Oncology 17(7):1134-1140

Cetuximab for treatment of metastatic colorectal cancer.
Cerea G, Ricotta R, Schiavetto I, Maugeri MR, Sartore-Bianchi A, Moroni M, Artale S, Siena S
Annals Oncology 17 S7:66-67

Anti-EGFR monoclonal antibodies in the treatment of non-small cell lung cancer.
Sartore-Bianchi A, Cerea G, Schiavetto I, Giannetta L, Ricotta R, Maugeri MR, Moroni M, Marrapese G, Siena S
Annals Oncology 17 S2:49-51

Cardiac toxicity of trastuzumab in metastatic breast cancer patients previously treated with high-dose chemotherapy: a retrospective study.
Bengala C, Zamagni C, Pedrazzoli P, Matteucci P, Ballestrero A, Da Prada G, Martino M, Rosti G, Danova M, Bregni M, Jovic G, Guarneri V, Maur M, Conte PF; Gruppo Italiano Trapianto Midollo Osseo (GITMO) Group
British Journal Cancer 94:1016-1020

Cloning of B cell lymphoma-associated antigens using modified phage-displayed expression cDNA library and immunized patient sera.
Cha SC, Kwak LW, Ruffini PA, Qin H, Neelapu S, Biragyn A
Journal Immunological Methods ;312:79-93

Idiotype-specific immunotherapy in multiple myeloma: suggestions for future directions of research.
Bogen B, Ruffini PA, Corthay A, Fredriksen AB, Froyland M, Lundin K, Rosjo E, Thompson K, Massaia M
Haematologica 91:941-948

Chemokine receptor targeting efficiently directs antigens to MHC class I pathways and elicits antigen-specific CD8+ T-cell responses.
Schiavo R, Baatar D, Olkhanud P, Indig FE, Restifo N, Taub D, Biragyn A
Blood 107:4597-4605

2005

Cell therapy of stage iv nasopharyngeal carcinoma with autologous EBV-targeted cytotoxic T-lymphocytes.
Comoli P, Pedrazzoli P, Maccario R, Basso S, Carminati O, Labirio M, Schiavo R, Secondino S, Frasson C, Perotti C, Moroni M, Locatelli F, Siena S
Journal Clinical Oncology 23(35):8942-8949

Treatment of metastatic neuroendocrine carcinomas based on WHO classification.
Artale S, Giannetta L, Cerea G, Pedrazzoli P, Schiavetto I, Napoletano M, Veronese S, Bramerio E, Gambacorta M, Vanzulli A, Pisconti S, Pugliese R, Siena S
Anticancer Research 25(6C):4463-4470

Survival and prognostic factors in patients with advanced renal cell cancer undergoing non-myeloablative allogeneic stem cell transplantation.
Peccatori J, Barkholt MP, Soriani MP, Bruzzi P, Ciceri F, Zambelli A, Da Prada GA, Pedrazzoli P, Siena S, Massenkeil K, Martino R, Lehoff S, Corradini P, Rosti G, Ringden O, Demirer T, Niederwieser D, Bregni M
Cancer 104(10):2099-2103

Somatic mutation of EGFR catalytic domain and treatment with gefitinib in colorectal cancer.
Moroni M, Sartore-Bianchi A, Benvenuti S, Artale S, Bardelli A, Siena S
Annals Oncology 16(11):1848-1849

Genetic idiotypic and tumor-cell-based vaccine strategies for indolent non-Hodgkin’s lymphoma.
Ruffini PA, Di Nicola M, Carlo-Stella C, Siena S, Gianni AM
Current Gene Therapy 5(5):511-521

Incidence of human cytomegalovirus infection in patients with refractory solid tumors receiving nonmyeloablative allogeneic stem cell transplants versus recipients of standard SCT for hematologic malignancies.
Zambelli A, Lilleri D, Pedrazzoli P, Peccatori J, Baldanti F, Fregoni V, Ciceri F, Caldera D, Renga M, Colombo AA, Alessandrino EP, Gerna G, Da Prada GA, Siena S, Bregni M
Biology Blood Marrow Transplantation 11(6):423-428

Survival of adults treated for medulloblastoma using paediatric protocols.
Spreafico F, Massimino M, Gandola L, Cefalo G, Mazza E, Landonio G, Pignoli E, Poggi G, Terenziani M, Pedrazzoli P, Siena S, Fossati-Bellani F
European Journal Cancer 41(9):1304-1310

HER1/EGFR inhibitor-associated rash: Future directions for management and investigation outcomes from the HER1/EGFR inhibitor rash management forum.
Pérez-Soler R, Delord JP, Halpern A, Kelly K, Krueger J, Massuti-Sureda B, von Pawel J, Temel J, Siena S, Soulieres D, Saltz L, Leyden J
Oncologist 10(5):345-356

Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to anti-EGFR treatment in colorectal cancer: a cohort study.
Moroni M, Veronese S, Benvenuti S, Marrapese G, Sartore-Bianchi A, Di Nicolantonio F, Gambacorta M, Bardelli A, Siena S
Lancet Oncology 6(5):279-286

Cardiac toxicity of high-dose chemotherapy.
Morandi P, Ruffini PA, Benvenuto GM, Raimondi R, Fosser V
Bone Marrow Transplantation 35:323-334

2004

Iron supplement in cancer patients receiving erythropoietin.
Pedrazzoli P, Tullio C, Cerea G, Siena S

Journal Clinical Oncology 22(21):4428-4429

High dose chemotherapy and hematopoietic progenitor cell transplantation for breast cancer.
Pedrazzoli P, Tarenzi E, Tullio C, Colosini G, Siena S

Journal Chemotherapy 16 Suppl 4:108-11

Evidence of graft-versus-tumour following allogeneic hematopoietic stem cell transplantation in renal cancer other than clear cell type.
Secondino S, Pedrazzoli P, Giannetta L, Schiavetto I, Vanzulli A, Siena S

Bone Marrow Transplantation 34(10):917-918

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer.
Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype C, Chau I, Van Cutsem E

New England Journal of Medicine 351(4):337-345

Ex vivo generation and expansion of anti-tumor cytotoxic T-cell lines derived from patients or their HLA-identical sibling.
Montagna D, Schiavo R, Gibelli N, Pedrazzoli P, Tonelli R, Pagani S, Assirelli E, Locatelli F, Pession A, Fregoni V, Montini E, Da Prada GA, Siena S, Maccario R

International Journal Cancer 110:76-86

Genetic fusions with viral chemokines target delivery of nonimmunogenic antigen to trigger antitumor immunity independent of chemotaxis.
Ruffini PA, Biragyn A, Coscia M, Harvey LK, Cha SC, Bogen B, Kwak LW

Journal Leukocyte Biology 76:77-85

Chemokine receptor-mediated delivery directs self-tumor antigen efficiently into the class II processing pathway in vitro and induces protective immunity in vivo.
Biragyn A, Ruffini PA, Coscia M, Harvey LK, Neelapu SS, Baskar S, Wang JM, Kwak LW

Blood 104:1961-1969

Randomized multicenter Phase II trial of two different schedules of irinotecan combined with capecitabine as first-line treatment in metastatic colorectal carcinoma.
Bajetta E, Di Bartolomeo M, Mariani L, Cassata A, Artale S, Frustaci S, Pinotti G, Bonetti A, Carreca I, Biasco G, Bonaglia L, Marini G, Iannelli A, Cortinovis D, Ferrario E, Beretta E, Lambiase A, Buzzoni R; Italian Trials in Medical Oncology (I.T.M.O.) Group

Cancer 100:279-287

Adoptive transfer of allogeneic Epstein-Barr virus (EBV)-specific cytotoxic T cells with in vitro antitumor activity boosts LMP2-specific immune response in a patient with EBV-related nasopharyngeal carcinoma.
Comoli P, De Palma R, Siena S, Nocera A, Basso S, Del Galdo F, Schiavo R, Carminati O, Tagliamacco A, Abbate GF, Locatelli F, Maccario R, Pedrazzoli P

Annals Oncology 15(1):113-117

2003

Optimising management of neutropenia and anaemia in cancer chemotherapy-advances in cytokine therapy.
Siena S, Secondino S, Giannetta L, Carminati O, Pedrazzoli P
Critical Review Oncology Hematology 48(Suppl):S39-47

Autologous hematopoietic stem cell transplantation for breast cancer in Europe: critical evaluation of data from the European Group for Blood and Marrow Transplantation (EBMT) Registry 1990-1999.
Pedrazzoli P, Ferrante P, Kulekci A, Schiavo R, De Giorgi U, Carminati O, Marangolo M, Demirer T, Siena S, Rosti G; European Group for Blood and Marrow Transplantation (EBMT), Solid Tumors Working Party
Bone Marrow Transplantation 32(5):489-494

Present results and perspectives of allogeneic non-myeloablative hematopoietic stem cell transplantation for treatment of human solid tumors.
Renga M, Pedrazzoli P, Siena S
Annals Oncology 14(8):1177-1184

Second-line chemotherapy with bleomycin, methotrexate, and vinorelbine (BMV) for patients with squamous cell carcinoma of the head, neck and esophagus (SCC-HN&E) pretreated with a cisplatin-containing regimen: a phase II study.
Moroni M, Giannetta L, Gelosa G, Secondino S, Chillura G, Colombo E, Siena S
Journal Chemotherapy 15(4):394-399

A combined analysis of two pivotal randomized trials of a single dose of pegfilgrastim per chemotherapy cycle and daily Filgrastim in patients with stage II-IV breast cancer.
Siena S, Piccart MJ, Holmes FA, Glaspy J, Hackett J, Renwick JJ
Oncology Reports 10(3):715-724

Absence of c-Kit and members of the epidermal growth factor receptor family in refractory germ cell cancer.
Moroni M, Schiavo R, Siena S, Veronese S
Cancer 97(11):2927-2928

A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy.
Green MD, Koelbl H, Baselga J, Galid A, Guillem V, Gascon P, Siena S, Lalisang RI, Samonigg H, Clemens MR, Zani V, Liang BC, Renwick J, Piccart MJ; International Pegfilgrastim 749 Study Group
Annals Oncology 14(1):29-35

2002

Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy.
Vansteenkiste J, Pirker R, Massuti B, Barata F, Font A, Fiegl M, Siena S, Gateley J, Tomita D, Colowick AB, Musil J; Aranesp 980297 Study Group
Journal National Cancer Institute 94(16):1211-1220

Therapeutic targeting of epidermal growth factor receptor with monoclonal antibodies.
Siena S, Artale S, Vanzulli A, Marrapese G, Bevilacqua L, Secondino S, Sironi O, Schiavo R, Moroni M, Pedrazzoli P
Tumori 1(4):S46-48

Raltitrexed plus oxaliplatin (TOMOX) as first-line chemotherapy for metastatic colorectal cancer. A phase II study of the Italian Group for the Study of Gastrointestinal Tract Carcinomas (GISCAD).
Cascinu S, Graziano F, Ferrau F, Catalano V, Massacesi C, Santini D, Silva RR, Barni S, Zaniboni A, Battelli N, Siena S, Giordani P, Mari D, Baldelli AM, Antognoli S, Maisano R, Priolo D, Pessi MA, Tonini G, Rota S, Labianca R
Annals Oncology 13(5):716-720

Allogeneic blood stem cell transplantation after a reduced-intensity, preparative regimen: a pilot study in patients with refractory malignancies.
Pedrazzoli P, Da Prada GA, Giorgiani G, Schiavo R, Zambelli A, Giraldi E, Landonio G, Locatelli F, Siena S, Della Cuna GR
Cancer 94(9):2409-2415

2001

Clinical results in 2001 show high dose therapy and hematopoietic progenitor cell transplantation as a therapeutic option for breast cancer.
Pedrazzoli P, Siena S
Haematologica 86(9):900-907

Epidermal growth factor receptor expression and activation in nonseminomatous germ cell tumors.
Moroni M, Veronese S, Schiavo R, Carminati O, Sorensen BS, Gambacorta M, Siena S
Clinical Cancer Research 7(9):2770-2775

H4(D10S170), a gene frequently rearranged in papillary thyroid carcinoma, is fused to the platelet-derived growth factor receptor beta gene in atypical chronic myeloid leukemia with t(5;10)(q33;q22).
Schwaller J, Anastasiadou E, Cain D, Kutok J, Wojiski S, Williams IR, LaStarza R, Crescenzi B, Sternberg DW, Andreasson P, Schiavo R, Siena S, Mecucci C, Gilliland DG
Blood 97(12):3910-3918

Pathophysiology, clinical manifestations and supportive care of metastatic brain cancer.
Riva M, Landonio G, Arena O, Citterio A, Galli C, Ferrante E, Brioschi A, Collice M, Gambacorta M, Scialfa G, Defanti CA, Siena S
Forum (Genova) 11(1):4-26

Controversies in the management of brain metastases: the role of chemotherapy.
Landonio G, Sartore-Bianchi A, Giannetta L, Renga M, Riva M, Siena S
Forum (Genova) 11(1):59-74

2000

Re: randomized trial of high-dose chemotherapy and blood cell autografts for high-risk primary breast carcinoma.
Pedrazzoli P, Bianchi AS, Renga M, Siena S
Journal National Cancer Institute 92(15):1271-1272

Platelet cryopreservation using second-messenger effector and low-dose (2%) dimethyl sulfoxide. In vitro evaluation of post-thawing platelet activity with the platelet function analyzer.
Borzini P, Lazzaro A, Mazzucco L, Schiavo R, Condor J, Siena S
Haematologica 85(8):885-887

The effect of anticonvulsant drugs on blood levels of methotrexate.
Riva M, Landonio G, Defanti CA, Siena S
Neurooncology 48(3):249-250

Breast cancer at the end of a successful century: meeting highlights from the First Milan Breast Cancer Conference and discussion paper for the Second Conference (Milan, 14-16 June, 2000).
Veronesi U, Costa A, Zurrida S, Goldhirsch A, Colleoni M, Cinieri S, Marsiglia H, Gelber S, Castiglione-Gertsh M, Jellins J, Cataliotti L, Sacchini V, Kurtz J, Dixon JM, Orvieto E, Braun S, Siena S
Breast 9:161-170

Therapeutic relevance of CD34 cell dose in blood cell transplantation for cancer therapy.
Siena S, Schiavo R, Pedrazzoli P, Carlo-Stella C
Journal Clinical Oncology 18:1360-1377

Transfusion of platelet concentrates cryopreserved with ThromboSol plus low-dose dimethylsulphoxide in patients with severe thrombocytopenia: a pilot study.
Pedrazzoli P, Noris P, Perotti C, Schiavo R, Ponchio L, Belletti S, Da Prada GA, Baldiuni CL, Salvaneschi L, Robustelli Della Cuna G, Siena S
British Journal Haematology 108(3):653-659

1999

Towards the integration of hematopoietic stem cells into therapy of breast cancer?
Siena S
Haematologica 84(10):865-867

New technology and changing parameters of leukapheresis for blood cell transplantation.
Granzow K, Schiavo R, Timofeeva I, Moroni G, Santoro A, Siena S.
Haematologica 84(8):752

New reciprocal translocation t(5;10)(q33;q22) associated with atypical chronic myeloid leukemia.
Siena S, Sammarelli G, Grimoldi MG, Schiavo R, Nozza A, Roncalli M, Mecucci C, Santoro A, Carlo-Stella C
Haematologica 84(4):369-372